The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2022 | Impact of the revised ELN-2017 AML recommendations
Amir Fathi, MD, MPH, Massachusetts General Hospital, Boston, MA, discusses the revised ELN-2017 recommendations for the diagnosis and treatment of acute myeloid leukemia (AML) in adults. Dr Fathi suggests that although new genetic evidence requires updated molecular definitions of AML, the new recommendations also present challenges with respect to the design of clinical trials and assessment of treatment response. This interview took place at the 64th ASH Annual Meeting and Exposition Congress held in New Orleans, LA. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consultancy – Genentech, BMS/Celgene, Foghorn, Kite, Morphosys, Abbvie, Takeda, Ipsen, Forma, Amgen, Novartis, Astellas, Immunogen, Mablytics, EnClear, Orum, PureTech, Daiichi Sankyo, Pfizer Research funding – BMS/Celgene, Abbvie, Agios/Servier
